Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Shareholder Meeting (May 2023)
14 slides from Telix Pharmaceuticals's shareholder meeting presentation, May 24, 2023
Slide 1: Annual General Meeting of Shareholders
Annual General Meeting of Shareholders Telix Pharmaceuticals (ASX:TLX) 11.00am AEST 24 May 2023
Slide 2: Important information
Important information This presentation is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This presentation contains summary information about Telix Pharmaceutica
Slide 3: Kevin McCann AO, Chairman
H Kevin McCann AO Chairman ©) Telix
Slide 4: Board of Directors
Board of Directors H Kevin McCann AO Christian Andreas Kluge Mark Nelson Tiffany Olson Jann Skinner Behrenbruch Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Director and Managing Director Director Director Director Director Chairman and Group CEO Note: Dr Andreas Kluge is cu
Slide 5: Meeting agenda
Meeting agenda 01 Chairman’s address 02 CEO’s address 03 Formal items of business, including voting and questions 5
Slide 6: Video
Video 6
Slide 7: Chairman's address
Annual General Meeting of Shareholders Chairman’s address H Kevin McCann AO 7
Slide 8: CEO's address
Annual General Meeting of Shareholders CEO’s address Dr Christian Behrenbruch 8
Slide 9: Delivering to our growth strategy
Delivering to our growth strategy Our key accomplishments in 2022 Commercialise the Unlock value in the Strengthen supply chain Expand the pipeline diagnostics portfolio therapeutic pipeline and manufacturing • $247M revenue from • ProstACT SELECT study • U.S. distribution network • Olaratumab (TLX3
Slide 10: Leadership in urologic oncology
Leadership in urologic oncology Building deep relationships with the Illuccix customer Supporting the urologic patient across the continuum of imaging, surgery and therapy Prostate Kidney Bladder cancer cancer cancer Diagnosis and staging Surgical technologies Therapy Advanced imaging Radio-guided s
Slide 11: Transition to a financially sustainable company
Transition to a financially sustainable company Continual improvement across key financial metrics Key expenditure ($M) and Adjusted EBITDAR ($M) percentage of sales 30.0 150% 40.0 27.4 130% 36.7 25.0 30.0 112% 110% 23.1 22.6 20.0 20.0 20.6 90% 22.1 18.3 15.0 70% 10.0 14.4 24.0 50% 22.1 20.9 10.0 20
Slide 12: Developing a world-class organisation
Developing a world-class organisation We have effectively scaled to optimise development and drive commercial success Commercial Development and Research & Early-Stage Clinical Development commercialisation Innovation Development (Phase III) Clinical Medical Alliance Operations Affairs Management Gl
Slide 13: Four major focus areas for 2023
Four major focus areas for 2023 Value creating catalysts across the imaging and therapeutic pipeline ProstACT New Drug Illuccix® - GLOBAL patient Biologics License Application (NDA) continued revenue recruitment and Application (BLA) for brain cancer growth and global ProstACT submission for imaging
Slide 14: Investor contact
Investor contact Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com Authorised for release to the ASX by the Telix Board of Directors 14
Telix Pharmaceuticals — Shareholder Meeting (May 2023) on 6ix